Literature DB >> 11528364

Adenomyosis demonstrates increased expression of the basic fibroblast growth factor receptor/ligand system compared with autologous endometrium.

A M Propst1, B J Quade, A R Gargiulo, R A Nowak, E A Stewart.   

Abstract

OBJECTIVES: Basic fibroblast growth factor (bFGF) is an angiogenic growth factor present in human endometrium and myometrium. Women with leiomyoma-related abnormal uterine bleeding have local dysregulation of bFGF and its type 1 receptor (FGF-R). This study was designed to evaluate if adenomyosis expresses bFGF and FGF-R, and if present, to compare bFGF and FGF-R expression in adenomyosis and autologous endometrium.
DESIGN: Menopausal uteri containing endometrium and adenomyosis were analyzed using immunohistochemistry with monoclonal antibodies specific for bFGF, FGF-R, and proliferating cell nuclear antigen (PCNA), a marker of cellular proliferation. The expression and intensity of staining for bFGF, FGF-R, and PCNA were evaluated in the glandular epithelium and stroma of adenomyosis and endometrium.
RESULTS: Glandular epithelial staining was significantly greater in adenomyosis compared with autologous endometrium for bFGF and FGF-R. Stromal staining for bFGF and PCNA was significantly increased in adenomyosis compared with autologous endometrium.
CONCLUSIONS: Upregulation of the bFGF receptor/ligand system and increased cellular proliferation in adenomyosis may contribute to the pathogenesis of abnormal uterine bleeding associated with adenomyosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528364     DOI: 10.1097/00042192-200109000-00012

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  4 in total

1.  Understanding adenomyosis: a case control study.

Authors:  F Andrei Taran; Amy L Weaver; Charles C Coddington; Elizabeth A Stewart
Journal:  Fertil Steril       Date:  2009-07-30       Impact factor: 7.329

2.  [The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis].

Authors:  Junyao Lou; Xiufeng Huang; Lifeng Zhang; Ping Xu; Xinmei Zhang; Zhengyun Chen
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-25

3.  Potential mechanisms of an antiadenomyosis chinese herbal formula shaoyao-gancao decoction in primary cell culture model.

Authors:  Yong-Ge Guan; Jin-Bin Liao; Kun-Yin Li; Yu-Cui Li; Yang Song; Jing Ling; Zi-Ren Su
Journal:  Evid Based Complement Alternat Med       Date:  2014-11-10       Impact factor: 2.629

4.  Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis.

Authors:  Ozgul Muneyyirci-Delale; David F Archer; Charlotte D Owens; Kurt T Barnhart; Linda D Bradley; Eve Feinberg; Veronica Gillispie; Sandra Hurtado; Jin Hee Kim; Alice Wang; Hui Wang; Elizabeth A Stewart
Journal:  F S Rep       Date:  2021-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.